Galapagos: Filgotinib remains a strong asset, whether on a standalone basis or in partnership

AbbVie released phase II top-line results for its KJAK inhibitor ABT-494 which met primary endpoint. In the meantime, the company announced it is to terminate the partnership agreement it had with GLPG as it will move its own programme in phase III. We believe that filgotinib has a significant potential in the RA space and that a partnership should be inked shortly.

For more information, please contact marketing@bryangarnier.com